Share

AstraZeneca profits dive

London - AstraZeneca, the British pharmaceutical giant, announced on Thursday a halving of net profits in the first quarter, hit by generic competition following the loss of exclusivity for key drugs.

Profit after tax slumped to $504bn in the three months to the end of March compared with $1.011bn during the first quarter of 2013, AstraZeneca said in an earnings statement.

The company, which is looking to push ahead with new treatments for cancer and respiratory disease, made no comment regarding weekend reports that US pharmaceutical giant Pfizer is considering a $100bn takeover of AstraZeneca.

On Thursday, the British group added that its pre-tax profits more than halved to $638m in the first quarter. Revenues edged up 0.5% to $6.416bn but by 3.0% at constant exchange rates.

AstraZeneca added that the impact of losses from major patent expiries, including for anti-cholesterol drug Crestor, totalled almost $150m in the first quarter.

In a bid to turn around the firm's fortunes, AstraZeneca is investing in its "rapidly progressing pipeline" of cancer drugs, chief executive Pascal Soriot said in Thursday's statement.

It is also shedding around 5 000 jobs under a three-year cost-cutting programme due to end in 2016.

The global pharmaceutical sector has undergone a huge shake-up this week after drugmakers Novartis and GlaxoSmithKline unveiled multi-billion-dollar deals also involving US group Eli Lilly.

The string of takeovers and ventures by the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and Eli Lilly strengthen its animal health unit.

The mega deals come as the global pharmaceutical industry is quickly shifting to deal with a raft of challenges, in particular patents expiring on key brands and deep cuts to government healthcare spending worldwide.

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Voting Booth
Do you think corruption-accused National Assembly Speaker Nosiviwe Mapisa-Nqakula will survive a motion of no confidence against her?
Please select an option Oops! Something went wrong, please try again later.
Results
No, her days are numbered
42% - 384 votes
Yes, the ANC caucus will protect her
58% - 525 votes
Vote
Rand - Dollar
18.94
-0.2%
Rand - Pound
23.91
-0.0%
Rand - Euro
20.43
+0.2%
Rand - Aus dollar
12.34
+0.1%
Rand - Yen
0.13
-0.2%
Platinum
910.50
+1.5%
Palladium
1,016.25
+1.4%
Gold
2,220.77
+1.2%
Silver
24.87
+0.9%
Brent Crude
86.09
-0.2%
Top 40
68,346
+1.0%
All Share
74,536
+0.8%
Resource 10
57,251
+2.8%
Industrial 25
103,936
+0.6%
Financial 15
16,502
-0.1%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE